Search
Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14587ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.
Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze, SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.25mlNisoldipine
go.drugbank.com/drugs/DB00401ApprovedBy inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. … Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.
International brands: Di Yi Xin, Ji Ni Le ErCategories: Calcium-Regulating Hormones and AgentsAlanosine
go.drugbank.com/drugs/DB05540InvestigationalAn amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.
Categories: Amino Acids, Peptides, and Proteins, Compounds used in a research, industrial, or household settingStreptococcus pneumoniae type 19a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10337ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 19a capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 19a of *Streptococcus pneumoniae
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheLancovutide
go.drugbank.com/drugs/DB05029InvestigationalLancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics. … Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.
Categories: Amino Acids, Peptides, and ProteinsSutilain
go.drugbank.com/drugs/DB09379ApprovedWithdrawn[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder.
Categories: Enzymes and CoenzymesFezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259591,A259542] NK3, one of the receptors expressed in KNDy neurons, is activated by neurokinin B and can thus induce the release of GnRH. … [A259591,A259542] By antagonizing NK3 receptors, neuronal signalling can be dampened to reduce VMS.
Categories: Genito Urinary System and Sex HormonesSynthetic Conjugated Estrogens, A
go.drugbank.com/drugs/DB09317ApprovedHowever, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control … Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone
Categories: Hormones, Hormone Substitutes, and Hormone AntagonistsTofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS).
Categories: Nucleic Acids, Nucleotides, and NucleosidesTebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigationalThis approval marks the first bispecific T cell engager to be approved by the FDA to treat a solid tumour and being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents